Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NSCLC, metastatic 2

2984 - IMpower150: clinical safety, tolerability and immune-related adverse events in a Phase III study of atezolizumab (atezo) + chemotherapy (chemo) _ bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

Date

21 Oct 2018

Session

Poster Discussion session - NSCLC, metastatic 2

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Presenters

Martin Reck

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

M. Reck1, T. Wehler2, F. Orlandi3, N. Nogami4, C. Barone5, D. Moro-Sibilot6, M. Shtivelband7, J.L. González Larriba8, J. Rothenstein9, M. Frueh10, G. Shankar11, A. Lee11, Y. Deng12, H. Patel13, C. Kelsch13, W. Lin14, M.A. Socinski15

Author affiliations

  • 1 Medical Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), 22927 - Grosshansdorf/DE
  • 2 Klinik Für Hämatologie, Onkologie Und Palliativmedizin Evangelisches, Evangelisches Krankenhaus Hamm gGmbH, Hamm/DE
  • 3 Medical Oncology, Instituto Nacional del Tórax, Prosalud Oncología, Santiago/CL
  • 4 Department Of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 5 Medical Oncology, Università Cattolica del Sacro Cuore, 168 - Roma/IT
  • 6 Thoracic Oncology Unit Shupp, Ptv, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble/FR
  • 7 Medical Oncology, Ironwood Cancer & Research Center, Chandler/US
  • 8 Servicio De Oncologia Medica, Hospital Clinico San Carlos, Madrid/ES
  • 9 Medical Oncology, Durham Regional Cancer Center, Lakeridge Health, L1G 2B9 - Oshawa/CA
  • 10 Department Of Medical Oncology/hematology, Cantonal Hospital of St. Gallen, 9007 - St. Gallen/CH
  • 11 Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 12 Biostatistics, Genentech, Inc., South San Francisco/US
  • 13 Safety Science, Genentech, Inc., South San Francisco/US
  • 14 Global Development Team, Genentech, Inc., South San Francisco/US
  • 15 Thoracic Oncology, Florida Hospital Cancer Institute, Orlando/US
More

Resources

Abstract 2984

Background

Atezo (anti–PD-L1) + bev + chemo prolonged PFS and OS vs bev + chemo in patients (pts) with 1L nonsquamous NSCLC in the randomized Phase III IMpower150 study. This combination was well tolerated and its safety profile was consistent with known safety risks. This study further evaluates safety, tolerability and immune-related AEs by treatment phase.

Methods

Pts received atezo 1200 mg + bev 15 mg/kg + carboplatin (C) AUC 6 + paclitaxel (P) 200 mg/m2 (Arm B) vs bev + CP (Arm C) IV q3w for 4 or 6 cycles per investigator decision, then maintenance atezo + bev or bev, respectively. AE incidence and severity in the induction and maintenance/follow-up phases were reported. Data cutoff: January 22, 2018.

Results

In the induction phase, 380/393 pts (97%) in Arm B and 389/394 pts (99%) in Arm C had an AE; 54% and 52% had Gr3-4, 4% and 3% had Gr5, and 29% and 27% had serious AEs, respectively. In the maintenance phase, 289/312 pts (93%) in Arm B and 219/270 pts (81%) in Arm C had an AE; 37% and 23% had Gr3-4, 3% had Gr5 in both arms, and 26% and 13% had serious AEs, respectively. 30% and 16% of pts received bev > 12 mo in Arms B and C. 36% of pts in Arm B received atezo > 12 mo. The incidence of AEs leading to all study treatment withdrawal in the induction phase was 6% and 5% in Arms B and C; chemo only withdrawal was 6% and 5% in Arms B and C. The incidence of AEs leading to bev withdrawal was 13% in both phases in Arm B and 11% and 9% in the induction and maintenance phases in Arm C; atezo withdrawal was 8% in Arm B in both phases. The incidence of immune-related AEs by treatment phase are shown in the table.

Conclusions

Atezo + bev + CP demonstrated a tolerable safety profile, with the majority of AEs occurring in the induction phase; most immune-related AEs observed were low grade. Incidence of AEs leading to treatment withdrawal were similar between arms, and withdrawal due to atezo or bev were similar across treatment phases.

Clinical trial identification

NCT02366143.

Legal entity responsible for the study

F. Hoffmann-La Roche AG.

Funding

F. Hoffmann-La Roche AG.

Editorial Acknowledgement

Emily Casey, PhD, of Health Interactions.

Disclosure

M. Reck: Honoraria for lectures and consultancy: Hoffmann-La Roche, Lilly, AstraZeneca, BMS, Celgene, Boehringer Ingelheim, MSD, Merck, Abbot, Novartis, Pfizer. T. Wehler: Honoraria, consulting/advisory role: Boehringer Ingelheim, Roche, MSD, Celgene, BMS, Lilly; Research funding: Boehringer Ingelheim, MSD, Roche, BMS. F. Orlandi: Honoraria for advisory boards: AstraZeneca, Amgen-Roche, Boehringer Ingelheim, MSD; Travel grants: MSD, AstraZeneca, Roche, BMS; Speaker: AstraZeneca, MSD, Roche; Research grants: Astellas, Amgen-Roche, AstraZeneca, Boehringer Ingelheim, MSD. N. Nogami: Honoraria: AstraZeneca, Pfizer Inc., Ono Pharmaceutical Co., LTD., Kyowa Hakko Kirin, Taiho Phamaceutical Co., Ltd., Chugai Pharmaceutical Co., LTD, Eli Lilly Japan, Boehringer Ingelheim, MSD KK. D. Moro-Sibilot: Speaker/advisory board: Eli Lilly, MSD, Roche, Novartis, BMS, AstraZeneca, Takeda, Boehringer Ingelheim. J. Rothenstein: Speaker/advisory board: AstraZeneca, BMS, Merck, Pfizer, Roche. M. Frueh: Research support: BMS and AstraZeneca; Honoraria to institution for advisory: MSD, Roche, AstraZeneca, BMS, Boehringer Ingelheim. G. Shankar, Y. Deng, H. Patel, C. Kelsch: Employee: Genentech Inc,. A. Lee: Employee and owns stock: Genentech Inc,. W. Lin: Employee and has ownership interest: Genentech Inc,. M.A. Socinski: Honoraria, speakers’ bureau, research funding: Genentech. All other authors have declared no conflicts of interest.Table: 1386PD

Immune-related AEs by treatment phase in arms B and C of IMpower150

Induction PhaseaMaintenance Phaseb
Incidence, n (%)Arm B: atezo + bev + CP (n = 393)Arm C: bev + CP (n = 394)Arm B: atezo + bev + CP (n = 312)Arm C: bev + CP (n = 270)
All GradeGrade 3-4All GradeGrade 3-4All GradeGrade 3-4All GradeGrade 3-4
AEs of special interest, including immune-related AEsc131 (33.3)30 (7.6)85 (21.6)12 (3.0)116 (37.2)20 (6.4)35 (13.0)1 (0.4)
Immune-related AEsc in ≥ 5 patients in any arm across treatment phases, n (%)
Rash81 (20.6)9 (2.3)46 (11.7)2 (0.5)48 (15.4)09 (3.3)0
Hepatitis Lab abnormalities31 (7.9) 27 (6.9)12 (3.1) 10 (2.5)17 (4.3) 17 (4.3)3 (0.8) 3 (0.8)27 (8.7) 25 (8.0)8 (2.6) 8 (2.6)14 (5.2) 14 (5.2)0 0
Hypothyroidism17 (4.3)1 (0.3)10 (2.5)041 (13.1)08 (3.0)0
Pneumonitis6 (1.5)3 (0.8)4 (1.0)1 (0.3)6 (1.9)2 (0.6)1 (0.4)1 (0.4)
Hyperthyroidism8 (2.0)1 (0.3)2 (0.5)09 (2.9)03 (1.1)0
Colitis4 (1.0)1 (0.3)2 (0.5)2 (0.5)6 (1.9)5 (1.6)00
a

Adverse events with an onset on or after the first study drug treatment and up to 1 day before the date of the first dose of the maintenance therapy.

b

Adverse events with an onset on or after the first dose of the maintenance therapy and up to the data cutoff date. The denominator for the maintenance/follow up phase is adjusted to patients who received at least 1 dose of study treatment during the maintenance phase.

c

Immune-related AEs were defined using MedDRA Preferred Terms that included both diagnosed immune conditions and signs/symptoms potentially representative of immune-related events, regardless of investigator-assessed causality.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.